This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness
Timeframe: Measured through 7 days after each vaccine dose at Month 0, 1, 3, and 6
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration
Timeframe: Measured through 7 days after each vaccine dose at Month 0, 1, 3, and 6
Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms
Timeframe: Measured through 7 days after each vaccination at Month 0, 1, 3, and 6
Number of Participants Reporting Adverse Events (AEs), by Relationship to Study Product
Timeframe: Measured through 30 days after each vaccination at Month 0, 1, 3, and 6
Number of Participants Reporting Adverse Events (AEs), by Severity Grade
Timeframe: Measured through 30 days after each vaccination at Month 0, 1, 3, and 6
Number of Participants Reporting Serious Adverse Events (SAEs)
Timeframe: Measured through Month 12
Number of Participants Reporting Adverse Events of Special Interest (AESIs)
Timeframe: Measured through Month 18
Number of Participants Reporting New Chronic Conditions (Requiring Medical Intervention for ≥ 30 Days)
Timeframe: Measured through Month 12
Number of Participants With Early Study Termination Associated With an AE or Reactogenicity
Timeframe: Measured through Month 12
Number of Participants With Study Product Discontinuation Associated With an AE or Reactogenicity
Timeframe: Measured through Month 6.5
Chemistry and Hematology Laboratory Measures - ALT(SGPT), AST, Alkaline Phosphatase.
Timeframe: Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6
Chemistry and Hematology Laboratory Measures - Creatinine.
Timeframe: Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6
Chemistry and Hematology Laboratory Measures - Hemoglobin.
Timeframe: Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6
Chemistry and Hematology Laboratory Measures - Lymphocytes, Neutrophils.
Timeframe: Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6
Chemistry and Hematology Laboratory Measures - Platelets, WBC.
Timeframe: Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6
Numbers of Participants With Grade 1 or Higher Local Laboratory Results.
Timeframe: Measured during screening, and 2 weeks after each vaccination at Month 0, 1, 3, and 6
Occurrence and Level of HIV-specific Total IgG Binding Antibody Response Breadth and Magnitude - Positive Response Rates.
Timeframe: Measured at Month 6.5
Occurrence and Level of HIV-specific Total IgG Binding Antibody Response Breadth and Magnitude - Magnitudes.
Timeframe: Measured at Month 6.5
Occurrence and Level of Anti -V1/V2 Scaffold IgG Binding Antibody Responses - Positive Response Rates.
Timeframe: Measured at Month 6.5
Occurrence and Level of Anti -V1/V2 Scaffold IgG Binding Antibody Response - Magnitudes.
Timeframe: Measured at Month 6.5
Occurrence and Level of Neutralizing Antibody Responses Against HIV-1 Isolates.
Timeframe: Measured at Month 6.5
Occurrence and Level of HIV-specific CD4+ T-cell Responses - Positive Response Rates.
Timeframe: Measured at Month 6.5
Occurrence and Level of HIV-specific CD4+ T-cell Responses - Magnitudes.
Timeframe: Measured at Month 6.5
Occurrence and Level of HIV-specific CD8+ T-cell Responses - Positive Response Rates.
Timeframe: Measured at Month 6.5
Occurrence and Level of HIV-specific CD8+ T-cell Responses - Magnitudes.
Timeframe: Measured at Month 6.5